

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins


Avacta shares up as flow tests receive CE mark for self-test use


Avacta confirms lateral flow tests can detect Omicron variant


(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant o...


IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US


(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approv...


Avacta and Novacyt await UK regulatory approval for Covid-19 tests


(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits ne...